{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:06:11Z","timestamp":1781953571312,"version":"3.54.5"},"reference-count":15,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Vodobatinib is a third\u2010generation Bcr\u2010Abl 1 inhibitor, being used in chronic myeloid leukemia treatment. Herein, we report a validated LC\u2013MS\/MS method for quantifying vodobatinib from rat dried blood spot (DBS) as per FDA guidelines. Methanol was used as a solvent to extract vodobatinib from the DBS discs. We used an isocratic method with a flow rate of 0.80\u2009mL\/min in an Atlantis dC<jats:sub>18<\/jats:sub> (50\u2009<jats:bold>\u00d7<\/jats:bold>\u20094.6\u2009mm, 3.0\u2009\u03bcm) column with a 2.00\u2009min run time. The retention of vodobatinib and the I.S. was ~1.15 and 1.05\u2009min. The MS\/MS ion transitions monitored for vodobatinib and I.S. were m\/z 454.20\u2009\u2192\u2009270.05 and 309.15\u2009\u2192\u2009251.15, respectively. The linearity range was 1.04\u20131039\u2009ng\/mL. All the evaluated validation parameters met the acceptance criteria. Hematocrit levels of 35% and 50% yielded consistent concentrations at both low and high QC levels, with accuracy of 1.00%\u20131.03% and precision below 10%, indicating no hematocrit effect. For intravenous dosing, AUC<jats:sub>0\u2013\u221e<\/jats:sub> was 9475\u2009ng\u00b7h\/mL (DBS) versus 10,109\u2009ng\u00b7h\/mL (plasma), and for oral dosing, <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> values were 568\u2009ng\/mL (DBS) versus 544\u2009ng\/mL (plasma). Oral bioavailability was nearly identical between matrices (98.7% for DBS vs. 97.9% for plasma), confirming the reliability of DBS sampling for PK studies of vodobatinib.<\/jats:p>","DOI":"10.1002\/bmc.70204","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:05:57Z","timestamp":1756375557000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of a Dried Blood Spot Method for the Determination of a Third\u2010Generation Bcr\u2010Abl 1 Inhibitor, Vodobatinib, in Small Volumes of Rat Blood: Application to a Pharmacokinetic Study"],"prefix":"10.1002","volume":"39","author":[{"given":"Ashok","family":"Zakkula","sequence":"first","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Madipelli","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Veerla","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama\u00a0Murthi","family":"Bestha","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kaddare","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-327X","authenticated-orcid":false,"given":"Sreekanth","family":"Dittakavi","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Mullangi","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics Laxai Life Sciences Pvt. Ltd  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2019.08.007"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149286"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139847"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152548"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166452"},{"key":"e_1_2_7_7_1","volume-title":"Guidance for Industry: Bioanalytical Method Validation","author":"DHHS","year":"2018"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4491"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P2.8-047"},{"key":"e_1_2_7_10_1","unstructured":"ICH.2022. \u201cM10 Bioanalytical Method Validation and Study Sample Analysis.\u201dInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.6077"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0624-2"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01087-x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4445"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105281"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.70087"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:20:27Z","timestamp":1760041227000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/bmc.70204"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70204","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2025-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70204"}}